Claro Advisors LLC Boosts Stake in Moderna, Inc. (NASDAQ:MRNA)

Claro Advisors LLC grew its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 22.8% in the third quarter, HoldingsChannel.com reports. The fund owned 6,811 shares of the company’s stock after purchasing an additional 1,265 shares during the period. Claro Advisors LLC’s holdings in Moderna were worth $455,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of MRNA. Commerzbank Aktiengesellschaft FI lifted its position in Moderna by 1.7% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after purchasing an additional 93 shares during the last quarter. CVA Family Office LLC raised its position in shares of Moderna by 21.6% during the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock valued at $64,000 after buying an additional 96 shares in the last quarter. McAdam LLC lifted its holdings in shares of Moderna by 1.1% during the 2nd quarter. McAdam LLC now owns 11,075 shares of the company’s stock worth $1,315,000 after acquiring an additional 117 shares during the last quarter. 180 Wealth Advisors LLC grew its position in Moderna by 1.1% in the second quarter. 180 Wealth Advisors LLC now owns 14,868 shares of the company’s stock worth $1,826,000 after acquiring an additional 160 shares in the last quarter. Finally, Concurrent Investment Advisors LLC increased its stake in Moderna by 7.9% in the second quarter. Concurrent Investment Advisors LLC now owns 2,413 shares of the company’s stock valued at $287,000 after acquiring an additional 177 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Up 7.2 %

MRNA opened at $39.51 on Tuesday. The stock has a market capitalization of $15.20 billion, a price-to-earnings ratio of -6.79 and a beta of 1.69. The firm has a 50 day moving average price of $58.56 and a 200-day moving average price of $96.68. Moderna, Inc. has a twelve month low of $35.80 and a twelve month high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.39) EPS. Equities research analysts forecast that Moderna, Inc. will post -9.43 earnings per share for the current year.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 1,321 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. This represents a 13.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders have sold 2,930 shares of company stock valued at $217,170. 15.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Leerink Partners reduced their price objective on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research report on Tuesday, September 17th. Bank of America decreased their price target on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a research note on Friday, September 13th. Jefferies Financial Group cut their price objective on shares of Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research note on Tuesday, October 15th. Wolfe Research assumed coverage on shares of Moderna in a research report on Friday. They issued an “underperform” rating and a $40.00 target price on the stock. Finally, TD Cowen reduced their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research note on Friday, September 13th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $86.33.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.